SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing market attention as the community rallies around its organic, meme-driven growth and a rejection of traditional, high-pressure marketing tactics. Investors are actively discussing the project's grassroots origins and the upcoming milestones intended to drive momentum and long-term engagement.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp is experiencing significant investor interest driven by its status as a low-float SPAC, leading to high volatility and multiple trading halts. The community is actively debating the potential for a massive price squeeze, with many users drawing parallels to other recent high-momentum SPAC runs while debating the sustainability of the current price action.

Alexandria Real Estate Equities, Inc. engages in the provision of space for lease. It offers properties for rent to life science, agriculture technology (agtech), and technology tenants. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities (ARE) is currently drawing significant attention from investors who view the stock as deeply undervalued due to its historically low price-to-FFO ratios and substantial discounts to net asset value despite owning premium life science assets. While the broader market sentiment remains cautious regarding high interest rates and biotech sector headwinds, the community is actively debating whether current levels represent a generational buying opportunity or a deeper long-term correction.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as investors highlight its "phygital" brand strategy, specifically citing its massive retail presence in major chains and the launch of the Pengu Visa Card as key drivers for long-term utility. The community is actively discussing accumulation opportunities and comparing the project's unique revenue-generating model against traditional meme coins during this market phase.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is seeing a massive surge in investor interest following strong earnings that highlighted record subscriber growth and a new multi-billion dollar share repurchase program. The community is sharply divided, with bulls pointing to the company's dividend reliability and successful strategic turnaround under new leadership, while bears remain skeptical, citing heavy debt loads and concerns over subscriber reporting metrics.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell is currently in the spotlight after the Dutch Court of Appeal overturned a landmark 2021 ruling that previously mandated the company to sharply reduce its carbon emissions. While investors and market participants are parsing the implications of this legal win on Shell's climate strategy and capital allocation, the stock continues to be influenced by broader energy sector volatility and the firm's ongoing efforts to balance transition goals with core fossil fuel profitability.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending as investors focus on the upcoming April 13, 2026, topline Phase 2/3 data readout for its lead program, Darovasertib, in metastatic uveal melanoma. Community sentiment is high, with active discussions centered on the potential for an accelerated approval filing and the company's strong cash position, while institutional options activity suggests significant anticipation for a major price move.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors is currently at the center of market volatility as investors weigh the impact of potential new U.S. export controls on Chinese chip manufacturing against the company's long-term growth prospects in the automotive and AI sectors. The community is actively debating whether the stock represents an oversold value opportunity or a risky play amid broader semiconductor sector uncertainty and shifting geopolitical trade regulations.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

Royal Caribbean is experiencing significant volatility as investors weigh strong booking demand and raised annual guidance against a quarterly revenue miss and concerns regarding the impact of weather-related disruptions. The broader cruise sector is facing downward pressure as the community actively debates whether the recent sell-off represents an overreaction to temporary operational hurdles or a signal of cooling consumer sentiment.

Aon Plc engages in the provision of risk, health, and wealth solutions. It focuses on risk capital including claim management, reinsurance, risk analysis, management, retention, and transfer; and human capital involving analytics, health and benefits, investments, pensions and retirement, talent and rewards, and workplace wellbeing. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Aon plc. - Ordinary Shares - Class A

Aon is trending following mixed Q4 earnings results that showcased organic revenue growth and strong operational execution, alongside ongoing discussions about its strategic capital allocation and reinsurance partnerships. Investors are actively debating the company's long-term valuation and resilience in the face of complex macroeconomic pressures and insurance sector volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6% - Here's Why

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% - Time to Sell...

JPMorgan Chase & Co. Buys 134,764 Shares of MoonLake Immunotherapeutics $MLTX

JPMorgan Chase & Co. increased its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 342.1% during the third quarter, according to the company in its most recent 13F filing with the...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has received a consensus recommendation of "Hold" from the sixteen analysts that are currently covering the firm, Marketbeat Ratings...

Insider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 3,750,000 Shares of Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) Director Bvf Partners P/Il sold 3,750,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the...

Bvf Partners P/Il Sells 3,750,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) Director Bvf Partners P/Il sold 3,750,000 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 12.8% - Here's Why

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 12.8% - Here's What Happened...

<ul class="summary-bullets"><li>Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion though the approach was rejected.</li><li>MoonLake over the weekend announced that two of its late-stage trials in Hidradenitis suppurativa (HS) showed that clinical responses continue to improve to Week 40.</li><li>Currently, FDA approved medicines for HS include Novartis’s Cosentyx and AbbVie’s Humira.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) garnered retail interest on Tuesday on the heels of the company announcing long-term results from its late-stage clinical trials in moderate-to-severe hidradenitis suppurativa.On Stocktwits, retail sentiment around MLTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.<stembedurl>https://www.stocktwits.com/Bigpapa46/message/649036046</stembedurl>Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion though the approach was rejected.Another user said that they are eyeing the stock breaching $19 levels.<stembedurl>https://www.stocktwits.com/Mr_GA/message/649091749</stembedurl>Yet another lauded the stock as the “Best buy in clinical biopharma,” while adding that it guarantees a “massive payday.”<stembedurl>https://www.stocktwits.com/Creisi/message/649090006</stembedurl><h2 class="st-heading-2">MoonLake’s Recent Data Reveal</h2>MoonLake over the weekend announced that two of its late-stage trials in Hidradenitis suppurativa (HS) showed that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving 75% reduction in abscess and inflammatory nodule count. Hidradenitis suppurativa (HS) is a chronic, noncontagious inflammatory skin condition causing painful, recurring lumps and abscesses, often leading to scarring and tunnels under the skin.According to MoonLake, the data sets a new standard in long-term lesion control of HS as approved drugs only reported similar reduction in symptoms for about 40% and 60% of subjects, respectively, at the 1-year mark of their respective pivotal trials.Currently, FDA approved medicines for HS include Novartis’s Cosentyx and AbbVie’s Humira.According to data from Koyfin, 12 of the 16 analysts covering MLTX rate it ‘Buy’ or higher while two rate ‘Hold’ and the remaining two rate it ‘Sell.’ The 12-month average price target on the stock is at $26.71, representing a potential upside of about 41%.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> slumped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-in-anticipation-of-upbeat-q1-delivery-numbers-after-america-expansion-efforts/cZE5cWMRIVp">Nio Stock Rallies In Anticipation Of Upbeat Q1 Delivery Numbers After America Expansion Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.

Equity

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.


MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.7%  - Here's What Happened

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 8.7% - Here's What Happened...

Research Analysts Issue Forecasts for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of MoonLake Immunotherapeutics in a report released on Monday, March 30th. HC Wainwright analyst R. Selvaraju anticipates that the company will...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from BTIG Research

BTIG Research reissued a "buy" rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Current Price	$17.96
Prev Close	$19.41
Open	$19.50
Dividend Yield	0.00%
50-Day Moving Average	$17.15
Beta	0.65
Avg. Volume	920,087.57
PE Ratio	-5.09

52-Week High	$62.75
52-Week Low	$5.95
Market Capitalization	$1.29B
EPS (Annual)	-$3.53
Price to Book	4.21
Revenue Per Employee	$0.00

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MLTX News

MLTXMoonLake Immunotherapeutics